Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Jan 24;2007(1):CD002819.
doi: 10.1002/14651858.CD002819.pub2.

Cyclophosphamide for multiple sclerosis

L La Mantia  1 , C Milanese, N Mascoli, R D'Amico, B Weinstock-Guttman
Affiliations
Meta-Analysis

Cyclophosphamide for multiple sclerosis

L La Mantia et al. Cochrane Database Syst Rev. .

Abstract

Background: Multiple sclerosis is a presumed cell-mediated autoimmune disease of the central nervous system. Cyclophosphamide (CFX) is a cytotoxic and immunosuppressive agent, used in systemic autoimmune diseases. Controversial results have been reported on its efficacy in MS. We conducted a systematic review of all relevant trials, evaluating the efficacy of CFX in patients with progressive MS.

Objectives: The main objective was to determine whether CFX slows the progression of MS.

Search strategy: We searched the Cochrane MS Group Trials Register (searched June 2006), Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3 2006), MEDLINE (January 1966 to June 2006), EMBASE (January 1988 to June 2006) and reference lists of articles. We also contacted researchers in the field.

Selection criteria: Randomised controlled trials (RCTs) evaluating the clinical effect of CFX treatment in patients affected by clinically definite progressive MS.CFX had to be administered alone or in combination with adrenocorticotropic hormone (ACTH) or steroids. The comparison group had to be placebo or no treatment or the same co-intervention (ACTH or steroids)

Data collection and analysis: Two reviewers independently decided the eligibility of the study, assessed the trial quality and extracted data. We also contacted study authors for original data.

Main results: Of the 461 identified references, we initially selected 70: only four RCTs were included for the final analysis. Intensive immunosuppression with CFX (alone or associated with ACTH or prednisone) in patients with progressive MS compared to placebo or no treatment (152 participants) did not prevent the long-term (12, 18, 24 months) clinical disability progression as defined as evolution to a next step of Expanded Disability Status Scale (EDSS) score. However, the mean change in disability (final disability subtracted from the baseline) significantly favoured the treated group at 12 (effect size - 0.21, 95% confidence interval - 0.25 to -0.17) and 18 months (- 0.19, 95% confidence interval - 0.24 to - 0.14) but favoured the control group at 24 months (0.14, CI 0.07 to 0.21). We were unable to verify the efficacy of other schedules. Five patients died; sepsis and amenorrhea frequently occurred in treated patients (descriptive analysis).

Authors' conclusions: We were unable to achieve all of the objectives specified for the review. This review shows that the overall effect of CFX (administered as intensive schedule) in the treatment of progressive MS does not support its use in clinical practice.

PubMed Disclaimer

Conflict of interest statement

The review was assembled, analysed and reported independently of any company. Dr L La Mantia has received travel expenses from Dompè Biotec pharmaceutical company for participating at one neurological meeting.

Update of

References

References to studies included in this review

Hauser 1983 {published data only}
    1. Fishbeck KH. Immunosuppression for multiple sclerosis (Letter) [comment on: N Engl J Med 1983; 308: 173‐80]. The New England Journal of Medicine 1983;309:239‐40. - PubMed
    1. Hauser SL, Dawson DM, Beal MF. Controlled randomized trial of high‐dose cyclophosphamide, plasmapheresis and ACTH in progressive multiple sclerosis (Abstract). Neurology 1982;32:A78.
    1. Hauser SL, Dawson DM, Lehrich JR, Beal FM, Kevy SV, Weiner HL. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis. Design of a clinical trial. Archives of Neurology 1983;40:687‐90. - PubMed
    1. Hauser SL, Dawson DM, Lehrich JR, Flint Beal M, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three‐arm study of high‐dose intravenous cyclophosphamide, plasma exchange and ACTH [comment in: N Engl J Med 1983; 309: 239‐40; comment in: N Engl J Med 1983; 309: 241; comment in: Lancet 1991; 337:1540‐1]. The New England Journal of Medicine 1983;308(4):173‐80. - PubMed
    1. Hauser SL, Dawson DM, Weiner HL, Lehrich JR, Beal MF, Millis JA, et al. immunosuppression for multiple sclerosis (Letter) [Comment on: N Engl J Med 1983; 308: 173‐80]. The New England Journal of Medicine 1983;309:241. - PubMed
Likosky 1991 {published data only}
    1. Likosky WH. Experience with cyclophosphamide in multiple sclerosis: The cons. Neurology 1988;38 Suppl 2:14‐8. - PubMed
    1. Likosky WH, Fireman B, Elmore R, Eno G, Gale K, Goode BG, et al. Intensive immunosuppression in chronic progressive multiple sclerosis: the kaiser study. Journal of Neurology, Neurosurgery & Psychiatry 1991;54:1055‐1060. - PMC - PubMed
    1. Likosky WH, Fireman B, Griffin C. Intensive cyclophosphamide immunosuppression in multiple sclerosis: a randomized blinded multicenter clinical trial (Abstract). Neurology 1987;37 Suppl 1:108.
The CCMSSG 1991 {published data only}
    1. Bullas RWM, Laupacis A, Vandervoort MK, Noseworthy JH. The cost effectiveness evaluation of the Canadian cooperative study of cyclophosphamide and plasma exchange in Multiple Sclerosis (abstract). Le Journal Canadien Des Sciences Neurologiques 1990;17:241.
    1. Currier RD, Haerer AF, Files JC, Morrison FS. Cyclophosphamide and plasma exchange in multiple sclerosis (comment on Lancet 1991; 337:441‐6). The Lancet 1991;337:1034.
    1. Khatri BO, Quillen MP, Hoffman RG. Cyclophosphamide and plasma exchange in multiple sclerosis (letter) Comments to Lancet 1991; 337: 441‐446). The Lancet 1991;337:1033.
    1. Noseworht HJ, Ebers Gc, Roberts R. Cyclophosphamide and multiple sclerosis (letter). Neurology 1994;44:579. - PubMed
    1. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the resulkts of a randomized, placebo controlled multiple sclerosis clinical trial. Neurology 1994;44:16‐20. - PubMed
Wender 1988 {published data only}
    1. Wender M, Tokarz‐Kupczyk E et Mularek O. Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH [Wczesne wyniki leczenia postaci przewlekle postepujacych stwardnienia rozsianego cyklofosfamidem i ACTH]. Neur Neurochir Pol 1988;22(5):399‐403. - PubMed
    1. Wender M, Tokarz‐Kupczyk E, Mularek O. Late results of the treatment of the chronic progressive form of multiple sclerosis with cyclophosphamide and ACTH [Odlegle wyniki leczenia postaci przewlekle postepujacej siwardnienia rozsianego intensywna immunosupresja]. Neurologia i Neurochirurgia Polska 1989;23(3):188‐92. - PubMed

References to studies excluded from this review

Aimard 1966 {published data only}
    1. Aimard G, Girard PF, Raveau J. Multiple sclerosis and autoimmunisation. Treatment with anti‐neoplastic drugs [Sclerose en plaques et procesus d'autoimmunosisation traiment par les anti‐mitotiques]. Lyon Medical 1966;215:345‐52. - PubMed
Carter 1988 {published data only}
    1. Carter JL, Dawson DM, Hafler DA, Fallis RG, Stazzone L, Orav J, et al. Cumulative experience with high‐dose intravenous CFX and ACTH therapy in chronic progressive multiple sclerosis. Annals of New York Academy Sciences 1988;540:535‐6. - PubMed
    1. Carter JL, Dawson DM, Hafler DA, Fallis RJ, Stazzone L, Hauser SL, et al. Five year Experience with Intensive Immunosuppression in progressive Multiple Sclerosis using high‐dose IV Cyclophosphamide plus ACTH ( Abstract). Neurology 1986;36(4 Suppl 1):264.
    1. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high‐dose IV CFX and ACTH in progressive MS: cumulative 6‐year experience in 164 patients. Neurology 1988;38 Suppl 2:9‐14. - PubMed
    1. Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophsophamide and monoclonal antibodies (comments). Rivista di Neurologia 1987;57(2):88‐91. - PubMed
Cendrowski 1973 {published data only}
    1. Cendrowski W. Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside. Acta Neurologica Belgica 1973;73:209‐919. - PubMed
D'Andrea 1990 {published data only}
    1. D'Andrea F, D'Aurizio C, Marini C, Prencipe M. Ciclophosphamide in remitting relapsing multiple sclerosis. Italian Journal of Neurological Sciences 1990;11:271‐4. - PubMed
D'Andrea 1991 {published data only}
    1. D'Andrea F, Mancini A, Marini C, Matteis G, Totaro R, Prencipe M. Clinical study with intravenous boluses of cyclophosphamide in relapsing‐remitting multiple sclerosis [Studio clinico con ciclofosfamide in pazienti con sclerosis multipla di tipo remittente]. Rivista di Neurobiologia. 1991;37(3):119‐22.
Delmont 2004 {published data only}
    1. Delmont E, Chanalet S, Bourg V, Soriani MH, Chatel M, Lebrun C. Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide‐methylprednisolone: predictive factors of treatment response. Revue Neurologique 2004;160(6‐7):659‐65. - PubMed
Drachman 1975 {published data only}
    1. Drachman DA, Paterson PY, Schmidt RT, Spehlman RF. Cyclophosphamide in exacerbations of multiple sclerosis: therapeutic trial and a strategy for pilot drug studies. Journal of Neurology, Neurosurgery & Psychiatry 1975;38:592‐7. - PMC - PubMed
Gauthier 2003 {published data only}
    1. Gauthier A, Bharanidharan P, Stazzone L, Smith DR, Dawson DM, Hafler DA, et al. Treatment of relapsing remitting interferon/glatiramer acetate unresponsive patients with pulse cyclophosphamide Ame. Acad Neurology 55th Annual Meeting (Abstract). Neurology. 2003; Vol. 60:A148.
Girard 1967 {published data only}
    1. Girard PT, Aimard G, Pellet H. Les immunodepresseurs en neurologie. Medycyna Pracy 1967;75:967. - PubMed
Gladstone 2006 {published data only}
    1. Gladstone DE, Zamkoff KW, Krupp L, Peyster R, Sibony P, Christodoulou C, et al. High‐dose cyclophsophamide for moderate to severe refractory multiple sclerosis. Archives of Neurology 2006;63(10):1388‐93. [MEDLINE: ] - PubMed
Gobbini 1999 {published data only}
    1. Gobbini MI, Smith ME, Richert NC, Frank JA, Farland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing‐remitting multiple sclerosis. Journal of Neuroimmunology 1999;99:142‐9. - PubMed
Gonsette 1977 {published data only}
    1. Gonsette RE, Demonty L, Delmotte P. Intensive immunosuppression with cyclophosphamode in multiple sclerosis. Follow‐up of 110 patients for 2‐6 years. Journal of Neurology 1977;214:173‐81. - PubMed
Goodkin 1987 {published data only}
    1. Goodkin DE, Plencner S, Palmer‐Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance versus Nonmaintenance therapy. Archives of Neurology 1987;44:823‐7. - PubMed
    1. Goodkin DE, Plencner S, Palmer‐Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis: maintenance versus non‐maintenance therapy (Abstract). Neurology 1986;36 Suppl 1:184. - PubMed
Gopel 1972 {published data only}
    1. Gopel W, Benkemstein H, Banzhaf M. Immunosuppressive therapy of multiple sclerosis usign cyclophosphamide and imuran. Report on 57 cases. Das Deutsche Gesundheitswesen 1972;27:1955‐61. - PubMed
Haerer 1991 {published data only}
    1. Haerer AF, Currier RD, Files JC, Morrison FS. Monthly intravenous cyclophosphamide for MS works, but it doesn't last (abstract). Neurology 1987;37 Suppl 1:289.
Hohol 1992 {published data only}
    1. Hohol MJ, Olek MJ. Pilot study of 3 years evaluating pulse cyclophosphamide and methylprednisolone versus methylprednisolone (abstract). Annals of neurology. 1992;32:256‐7.
Hohol 1999 {published data only}
    1. Hohol MJ, Holek MJ, Orav EJ, Stazzone L, Hafler BA, Khoury St, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy linked to the duration of progressive disease. Multiple Sclerosis 1999;5:403‐9. - PubMed
Hommes 1975 {published data only}
    1. Hommes OR, Prick JJG, Lamers KJB. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clinical Neurology and Neurosurgery 1975;78:59‐72. - PubMed
Hommes 1980 {published data only}
    1. Hommes OR, Lamers KJB, Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. Journal of Neurology 1980;223:177‐90. - PubMed
Huston 1983 {published data only}
    1. Huston DP, White MJ, Bressler RB, Rivera VM, Cooper B, Killian JM. Immunosuppression for multiple sclerosis (Letter) [comment on: N Engl J Med 1983; 308: 173‐80]. The New England Journal of Medicine 1983;309:239‐40.
Khan 2001 {published data only}
    1. Khan OA, Zvartau‐Hind M, Caon C, Din MU, Cochran M, Lisak D, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to convemtional therapy. Multiple Sclerosis 2001;7:185‐8. - PubMed
Khatri 1984 {published data only}
    1. Khatri BO, Koethe SM, Mc Quillen. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study. Archives of Neurology 1984;41:734‐8. - PubMed
    1. Khatri BO, Quillen MP, Koethe S. Plasmapheresis and combined immunosuppressive drug therapy in chronic progressive multiple sclerosis. Chosing the patient who should respond. Annals of the New York Academy of Sciences. 1984;436:389‐96. - PubMed
Khatri 1985 {published data only}
    1. Khatri BO, Quillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double‐blind controlled study of plasma pheresis in patients taking immunosuppressive drugs. Neurology 1985;35:312‐9. - PubMed
Khatri 1991 {published data only}
    1. Khatri BO. Experience with use of plasmapheresis in chronic progressive multiple sclerosis: the pros. Neurology 1988;38 Suppl 2:50‐2. - PubMed
    1. Khatri BO, McQuillen MP, Hoffman RG, Harrington GJ, Schmoll D. Plasma exchange in chronic progressive multiple sclerosis. A long term study. Neurology 1991;41:409‐14. - PubMed
Killian 1988 {published data only}
    1. Killian JM, Bressler RB, Armostrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Archives of Neurology 1988;45:27‐30. - PubMed
Kornhuber 1986 {published data only}
    1. Kornhuber HH, Mauch E. Immunosuppressive Cyclophosphamide‐Therapy for multiple sclerosis [Immunsuppressive Cyclophosphamid‐Therapie der multiplen Sklerose mit wenig Nebenwirkungen]. Deutsche Medizinische Wochenschrift 1986;111(46):111. - PubMed
Kornhuber 1987 {published data only}
    1. Kornhuber HH, Mauch E, Petru E, Schmahl. Risk of malignancies of cyclophosphamide therapy in multiple sclerosis [Zum Malignitatsrisiko bei cyclophosphamid‐therapie der multiplen Sklerose]. Deutsche Medizinische Wochenschrift 1987;112(13):330. - PubMed
La Mantia 1997 {published data only}
    1. Mantia L, Eoli M, Salmaggi A, Milanese C. The efficacy of different cyclophosphamide treatment schedules in progressive multiple sclerosis patients (Abstract). Journal of Neurology 1997;244:S85. - PubMed
    1. Mantia L, Eoli M, Salmaggi A, Torri V, Milanese C. Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Italian Journal of Neurological Sciences 1998;19:32‐6. - PubMed
Laterre 1989 {published data only}
    1. Laterre C, Sindic CJM, Heule H. Oral cyclophosphamide treatment in multiple sclerosis. In: Gonsette RE, Delmotte P editor(s). Recent advances in multiple sclerosis therapy. Elsevier Science Pub BV, 1989:147‐50.
Lebrun 2006 {published data only}
    1. Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy‐induced fatigue. Multiple Sclerosis 2006;12(3):321‐4. - PubMed
Mancardi 2001 {published data only}
    1. Mancardi GL, Saccaridi R, Filippi M, Gualandi F, Murialdo A, Inglese M, et al. Autologous hematopoietic stem cell transplantation suppress Gd‐enhanced MRI activity in MS. Neurology 2001;57(1):62‐8. - PubMed
Manova 2000 {published data only}
    1. Manova MG, Kostadinova IJ, Rangerlov AA. Clinico‐laboratory study of methylprednisolone and cyclophosphamide tretament in patients with multiple sclerosis relapse. Folia Medica 2000;42(3):20‐5. - PubMed
Manova 2001 {published data only}
    1. Manova MG, Kostadinova IJ, Chalakova‐Atanasova NT, Temlieva VK, Petrova NS. Clinico‐electrophysiological correlates in patients with relpsing remitting multiple sclerosis. Folia Medica 2001;43(3):5‐9. - PubMed
Mauch 1989 {published data only}
    1. Mauch E, Kornhuber HH, Pfrommer U, Hahnel A, Laufen H et Krapf H. Effective treatment of chronically progressive multiple sclerosis with low dose cyclophosphamide with minor side effects. European Archives of Psychiatry and Neurological Sciences 1989;238:115‐7. - PubMed
Merico2002 {published data only}
    1. Merico A, Levedianos S, Gallo P, Zanco P, Piccione F, Tonin P. Evaluation of myocardial functional parameters during intravenous cyclophosphamide pulse therapy: a case report. Mult Scler 2002;8(2):179. - PubMed
Mickey 1987 {published data only}
    1. Mickey MR, Ellison GW, Fahey JL, Moody DJ, Myers LW. Correlation of clinical and immunologic states in multiple sclerosis. Archives of Neurology 1987;44:371‐5. - PubMed
Millac 1969 {published data only}
    1. Millac P, Miller H. Cyclophosphamide in multiple sclerosis. Lancet 1969;1:783. - PubMed
Millefiorini 1990 {published data only}
    1. Millefiorini E, Giovanni M, Bernardi S, Grasso MG, Giampietro A, Gambi D. 24‐month follow‐up of multiple sclerosis patients treated with cyclophosphamide. Italian Journal of Neurological Sciences 1990;11:605‐7. - PubMed
Myers 1987 {published data only}
    1. Myers LW. The use of cyclophosphamide to treat multiple sclerosis. Review. Clinical Neuropharmacology. Vol. 10, New York: Raven Press, 1987:155‐61. - PubMed
    1. Myers LW, Fahey JL, Moody DJ, Mickey MR, Frane MV, Ellison GW. Cyclophosphamide "pulses" in chronic progressive multiple sclerosis. A preliminary clinical trial. Archives of Neurology 1987;44:828‐32. - PubMed
Paradowski 1999 {published data only}
    1. Paradowski B, Gruszka E, Pokryszko A. The comparison of the effectiveness of tretament of mutliple sclerosis relapse with high‐doses of mtehylprednislone, alpha‐24 corticotropin and cyclophosphamide. Polski Merkuriusz Lekarski 1999;6(36):305‐7. - PubMed
Patti 2001 {published data only}
    1. Patti F, Cataldi M, Nicoletti F, Reggio E, Nicoletti A, Reggio A. Combination of cyclophosphamide and interferon beta halst progresison in patients with rapidly transitional sclerosis. Journal Neurology Neurosurgery and Psychiatry 2001;71(3):404‐7. - PMC - PubMed
    1. Patti F, Reggio E, Fiorilla T, Nicoletti A, Palermo F, Reggio A. Rapidly transitional multiple sclerosis patients tretaed with combination of cyclophosphamide and interferon beta: follow up 36 months after discontinuation, 55 Annual meeting March‐April 2003. Neurology. 2003; Vol. 60:A148.
Patti 2004 {published data only}
    1. Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. A double blind, placebo‐controlled , phase II, add‐on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon‐beta study denomination: CYCLIN. Journal of Neurological Sciences 2004;223(1):69‐71. - PubMed
Patti 2004 a {published data only}
    1. Patti F, Reggio E, Palermo F, Fiorilla T, Politi G, Nicoletti A, et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Journal of Neurology 2004;251(12):1502‐6. - PubMed
Perini 2003 {published data only}
    1. Perini P, Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. Journal of Neurology 2003;250(7):834‐8. - PubMed
Perini 2006 {published data only}
    1. Perini P, Calabrese M, Tiberio M, Ranzato F, Battistin L, Gallo P. Mitoxantrone versus cyclophosphamide in secondary‐ progressive multiple sclerosis: a comparative study. Journal of Neurology 2006;253(8):1034‐40. - PubMed
Portaccio 2003 {published data only}
    1. Portaccio E, Zipoli V, Siracusa G, Piacentini S, Sorbi S, Amato MP. Safety and tolerability of cyclophosphamide ' pulses' in multiple sclerosis: a prospective study in a clinical cohort. Multiple Sclerosis 2003;9:446‐50. - PubMed
Reggio 2005 {published data only}
    1. Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing‐remitting multiple sclerosis patients. Twenty‐four months follow‐up. Journal of Neurology 2005;252(10):1255‐61. - PubMed
Rensel 1999 {published data only}
    1. Rensel MR, Cohen J, Kinkell RP, Ransohoff R, Cohen J, Rudick R, et al. Tolerability and effectiveness of monthly cyclophosphamide and methylprednisolone pulses in MS patients who deteriorate despite standard therapy (abstract). Neurology 1999;52:579.
Rivera 1988 {published data only}
    1. Rivera VM, Baralt T, Breitbach W, Ramirez A, Salinas H. Chronic periodic intravenous cyclophosphamide in progressive multiple sclerosis (Abstract). Neurology 1988;38:221.
Salmaggi 1994 {published data only}
    1. Salmaggi A, Milanese C, Eoli M, Mantia L, Nespolo A, Dufour A. Immunological monitoring and clinical evaluation in cyclophosphamide ‐ treated progressive multiple sclerosis patients. The International Journal of Neuroscience 1994;76:305‐12. - PubMed
Siracusa 1987 {published data only}
    1. Siracusa GF, Amato MP, Fratiglioni L, Sità D, Amaducci L. Short‐term intensive cyclophosphamide tretament in progressive multiple sclerosis. Italian Journal of Neurological Sciences 1987;8:589‐92. - PubMed
Smith 2003 {published data only}
    1. Smith DR, Weinstock‐Guttman B, Cohen JA, Guttman C, Wie X, Stuart WH, et al. Blinded ‐randomized trial of pulse cyclophosphamide in IFN‐beta resistant active MS. American academy of Neurology 55th Annual Meeting (abstract). Neurology. 2003; Vol. 60:A84.
Smith 2004 {published data only}
    1. Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN‐Beta‐resistant active MS. Journal of Neurological Sciences 2004;223(1):73‐9. - PubMed
Smith 2005 {published data only}
    1. Smith DR, Weinstock‐Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, Olek M, Stone L, Greenberg S, Stuart D, Orav J, Stuart W, Weiner H. A randomized blinded trial of combination therapy with cyclophosphamide in patients‐with active multiple sclerosis on interferon beta. Multiple Sclerosis 2005;11(5):573‐82. - PubMed
Trouillas 1989 {published data only}
    1. Trouillas P, Neuschwander P, Nighoghossian N, Adeleine P et Tremisis P. Intensive immunosuppressive therapy of progressive multiple sclerosis. Results at 3‐year follow up of an open study to compare cyclophosphamide alone or combined with plasma exchange and controls [Immunosuppression intensive dans la sclerose en plaques progressive. Etude ouverte comparant trois groupes: cyclophosphamide, cyclophosphamide‐plasmaphereses et temoins. Resultats a trois ans]. Revue Neurologique 1989;145(5):369‐77. - PubMed
Weiner 1989 {published data only}
    1. Weiner HL, Dau PC, Khatri BO, Birbaum G, McQuillen MP, Fosburg M, et al. Double‐blind study of true versus sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis (Abstract). Neurology 1988;38 Suppl 1:256. - PubMed
    1. Weiner HL, Dau PC, Khatri BO, Petajan J, Bimbaum G, Quillen MP, et al. Double‐blind study of true vs sham plasmapheresis in patients treated with immunosuppression for acute attacks of multiple sclerosis. Progress in clinical and biological research. 1990;337:283. - PubMed
    1. Weiner HL, Dau PC, Khatri BO, Petajan JH, Birbaum G, McQuillen MP, et al. Double‐blind study of true versus sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39(9):1143‐9. - PubMed
Weiner 1993 {published data only}
    1. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Final report of the Northeast Cooperative Multiple Sclerosis Tretament Group. Neurology 1993;43:910‐8. - PubMed
Weinstock‐Guttman 97 {published data only}
    1. Weinstock‐Guttman B, Kinkel RP, Cohen JA, Ransohoff RM, Schwetz K, Gogol D, et al. Treatment of fulminant multiple sclerosis with intravenous cyclophosphamide. The Neurologist 1997;3:178‐85.
Zefir 2002 {published data only}
    1. Zephir H, Seze J, Senechal O, Stojkovic T, Ferriby D, Deliss B, et al. Treatment of progressive multiple sclerosis with cyclophosphamide. Revue Neurologique 2002;158(1):65‐9. - PubMed
Zefir 2003 {published data only}
    1. Zephir H, Seze J, Duhamel A, Debouverie M, Lebrun C, Malikova I, et al. Treatment of progresive forms of multiple sclerosis by cyclophosphamide . A cohort study of 490 patients. Ame Academy of Neuorlogy . 55 th Annual Meeting (abstract). Neurology. 2003; Vol. 60:A 148.
Zephir 2004 {published data only}
    1. Zephir H, Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. Journal of Neurological Sciences 2004;218(1‐2):73‐7. - PubMed
Zephir 2005 {published data only}
    1. Zephir H, Seze J, Dujardin K, Dubois G, Cabaret M, Bouillaguet S, et al. One‐year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis. Multiple Sclerosis 2005;11(3):360‐3. - PubMed

Additional references

Boumpas 1992
    1. Boumpas DT, Austin III HA, Vaughn EM, Klippel JH, Steimberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340(8822):741‐5. [MEDLINE: ; EMBASE‐92296667] - PubMed
Calabresi 1991
    1. Calabresi P, Chabner BA. Antineoplastic agents. In: Goodman, Gillman's. Hardman JG Limbird LE, Molinoff PB, Ruddon RW, Goodman Gillman A editor(s). Goodman & Gillman's. The pharmacological basis of therapeutics. Eighth. Vol. II, New York: Pergamon Press, 1991:1209‐23.
DeRidder 1998
    1. DeRidder D, VanPoppel H, Demonty L, D'Hooghe B, Gonsette R, Carton H, et al. Bladder Cancer in patients with multiple sclerosis treated with cyclophosphamide. The Journal of Urology 1998;159:1881‐4. - PubMed
Fraiser 1991
    1. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxcicity. Characteristics and avoiding the problems [Review]. Drugs 1991;42(5):781‐95. [MEDLINE: ; EMBASE‐92004520] - PubMed
Hommes 2004
    1. Hommes OR, Weiner HL. Clinical practice of immunosuppressive treatments in multiple sclerosis:results of a second international questionnaire. Journal of Neruological Sciences 2004;223:65‐7. - PubMed
Jadad 1996
    1. Jada AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
Kurtzke 1983
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11):1444‐52. [MEDLINE: ] - PubMed
Lublin 1996
    1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907‐11. [MEDLINE: ; EMBASE‐96125709] - PubMed
Mc Guire 2003
    1. McGuire TR, Gwilt P, Manouvilov K, Healey K, Ursick MM, Nasch RA, et al. High‐dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation. International Immunopharmacology 2003;3(2):279‐83. - PubMed
McDonald 1977
    1. McDonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis [Review]. British Medical Bulletin 1977;33(1):4‐9. [MEDLINE: ] - PubMed
Noseworthy 1994
    1. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo‐controlled multiple sclerosis clinical trial. Neurology 1994;44:16‐20. - PubMed
Paterson 1974
    1. Paterson PY, Drobisah DG, Ginsberg MM. Experimental allergic encephalomyelitis in cyclophosphamide‐treated Lewis rats. Clinical remissions and relapse and effect of treatment in neuro‐fibrin deposits. Clinical Immunologic Immunopathology 1974;2:456‐64.
Poser 1983
    1. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227‐31. [MEDLINE: ] - PubMed
Rudick 2002
    1. Rudick RA, Cutter G, Reingol S. Multiple sclerosis Functional Composite : a new measure for clinical outcome in multiple sclerosis. Multiple sclerosis 2002;8:359‐65. - PubMed
Schluep 1997
    1. Schluep M, Bogousslavsky J. Emerging treatments in Multiple Sclerosis [Review]. European Neurology 1997;38(3):216‐21. [MEDLINE: ; EMBASE‐97308584] - PubMed
Sen 1991
    1. Sen RP, Walsh TE, Fiusher W, Brock N. Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest 1991;99(1):143‐6. [MEDLINE: ; EMBASE‐91047921] - PubMed
Talar‐Williams 1996
    1. Talar‐Williams C, Hijazi YM, Walther MM, Linehan WM, Hallaban CW, Lubensky I. Cyclophosphamide‐induced cystitits and bladder cancer in patients with Wegener granulomatosis. Annals of Internal Medicine 1996;124:477‐84. - PubMed
Thompson 2002
    1. Thompson AJ. Developing clinical outcome measures in multiple sclerosis: an evolving process. Multiple Sclerosis 2002;8:357‐358. - PubMed
Weiner 1990
    1. Weiner HL, Dau PC, Khatri BO, Petajan J, Bimbaum G, Quillen MP, et al. Double‐blind study of true vs sham plasmapheresis in patients treated with immunosuppression for acute attacks of multiple sclerosis. Progress in clinical and biological research. 1990;337:283. - PubMed
Weiner 2002
    1. Weiner HI, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review and immunologic effects. Multiple sclerosis 2002;8(2):142‐54. - PubMed
Wender 1989
    1. Wender M, Tokarz‐Kupczyk E, Mularek O. Late results of the treatment of the chronic progressive form of multiple sclerosis with cyclophosphamide and ACTH [Odlegle wyniki leczenia postaci przewlekle postepujacej siwardnienia rozsianego intensywna immunosupresja]. Neurologia i Neurochirurgia Polska 1989;23(3):188‐92. - PubMed

MeSH terms